Skip to contentW
West Pharmaceutical Services Inc
W
WSTWest Pharmaceutical Services Inc Q2 2025 · 10-Q
Revenue$766.50M$766.50M+9.2% vs Q2 2024 Net Income$131.80M$131.80M+18.4% vs Q2 2024 EPS Diluted$1.82$1.82+20.5% vs Q2 2024 Gross Profit$273,900,000+19.1% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
West Pharmaceutical Services Inc · CIK 105770 · Engraved from SEC EDGAR
Operating Cash Flowderived$177,100,000+7.3% Free Cash Flowderived$101,900,000+57.3% Margins · derivedGross margin35.7%+3.0 pt vs Q2 2024
Operating margin20.1%+2.1 pt vs Q2 2024
Net margin17.2%+1.3 pt vs Q2 2024
ended Jun 30, 2025 · filed Jul 24, 2025 · 24 d after period end